Trinity Biotech PLC (TRIB) — SEC Filings
Trinity Biotech PLC (TRIB) — 50 SEC filings. Latest: 6-K (May 6, 2026). Includes 47 6-K, 1 20-F, 1 SC 13D/A.
View Trinity Biotech PLC on SEC EDGAR
Overview
Trinity Biotech PLC (TRIB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Mar 25, 2026: TRINITY BIOTECH PLC filed a 6-K on March 25, 2026, indicating a routine report for foreign issuers. This filing, with accession number 0001178913-26-001700, includes a 6-K document, an EX-99.1 exhibit, and a graphic. For investors, this filing is a standard disclosure and doesn't reveal new financia
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 8 bullish, 42 neutral. The dominant filing sentiment for Trinity Biotech PLC is neutral.
Filing Type Overview
Trinity Biotech PLC (TRIB) has filed 47 6-K, 1 20-F, 1 SC 13D/A, 1 20-F/A with the SEC between Jul 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of TRIB's 45 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 36 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Susan O'Connor
- Michael McNamee
- Joseph Edelman
- Alexander Rakitin
- Adrian Donohue
Top Tags
sec-filing (17) · foreign-private-issuer (15) · reporting (11) · 6-K (9) · routine-report (5) · regulatory-filing (4) · healthcare (4) · 6-k (4) · annual-report (3) · regulatory-approval (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Minimum Shareholder Approval | 93% | Indicates strong shareholder confidence in management's proposals. |
| Minimum Bid Price | $1.00 | The closing bid price requirement to regain Nasdaq compliance. |
| AI Wearable Market Size | $260 billion | Represents the significant market opportunity for Trinity Biotech's new CGM+ platform. |
| Fiscal Year End | 2024 | The period covered by the 20-F filing. |
| PPP Loan Income (2021) | $4.4 million | Non-taxable income reported in a prior year, relevant to 'other items' discussion. |
| Form Type | 20-F/A | Indicates this is an amendment to a Form 20-F filing. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Trinity Biotech PLC (TRIB)?
Trinity Biotech PLC has 50 recent SEC filings from Jul 2024 to May 2026, including 47 6-K, 1 20-F, 1 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TRIB filings?
Across 50 filings, the sentiment breakdown is: 8 bullish, 42 neutral. The dominant sentiment is neutral.
Where can I find Trinity Biotech PLC SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Trinity Biotech PLC (TRIB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Trinity Biotech PLC?
Financial highlights for Trinity Biotech PLC are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for TRIB?
Investment thesis data for TRIB will be available once enriched filings are processed.
Who are the key executives at Trinity Biotech PLC?
Key executives identified across Trinity Biotech PLC's filings include Susan O'Connor, Michael McNamee, Joseph Edelman, Alexander Rakitin, Adrian Donohue.
What are the main risk factors for Trinity Biotech PLC stock?
Of TRIB's 45 assessed filings, 0 were flagged high-risk, 9 medium-risk, and 36 low-risk.
What are recent predictions and forward guidance from Trinity Biotech PLC?
Forward guidance and predictions for Trinity Biotech PLC are extracted from SEC filings as they are enriched.